Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/20/2025

Hormone Therapy in Male-to-Female Transition

Gastrointestinal Effects

  • Estrogen treatment in male-to-female transition can lead to bowel distension as a side effect, primarily due to estrogen's effects on gastrointestinal motility, according to the American College of Physicians 1
  • The hyperestrogenic state created during MTF hormone therapy can lead to physiological changes similar to those seen in cisgender women with high estrogen levels, resulting in changes in bowel function 1
  • Gender-affirming hormone treatment (GAHT) with estrogen induces changes in body composition, including increases in fat mass, as stated by the World Health Organization 2

Management of Gastrointestinal Side Effects

  • For individuals experiencing bowel distension during MTF transition, consider transdermal rather than oral estrogen, as oral administration has more pronounced effects on hepatic protein synthesis that may influence GI function, recommended by the Endocrine Society 3

Individual Considerations

  • Not all transgender women will experience bowel distension; response to hormone therapy varies between individuals, highlighting the importance of individualized care 1
  • Regular follow-up with healthcare providers is essential to address side effects and monitor the effectiveness of hormone therapy, as advised by the American Medical Association 1

Benefits and Risks

  • The benefits of gender-affirming hormone therapy for transgender women, including improved psychological well-being and reduced gender dysphoria, should be weighed against the potential risk of gastrointestinal side effects, as suggested by the American Psychological Association 1

REFERENCES